An Essay on Safety of Drugs Focusing on Adverse Drug Reaction Problems in Japan (Papers Presented at the International Symposium on Safety Control and Risk Management, SCRM) by Yamamoto Haruhiko
An Essa on Sa Drugs
Focusing on Adverse Drug Reaction Problems in Japan 
Haruhiko  Yamamoto'
* Foundation for Adverse Drug Reaction 
 Inovatory Research of Drug, Sunshine 
 Higashi-Ikebukuro, Toshima-ku, Tokyo,
Sufferings Relief and 
Bldg. 60 (26th Floor), 
170 JAPAN
Advancement of 
 1-1, 3 chyome,
-- 93 -
 Introduct"on 
      In the long history of faighting against diseases, we had not had 
effective drugs for therapeutic practices, except for only a few drugs like 
morphine, digitalis, arsphenamine, liver extract(vitamin B12), insulin, nico-
tinic acid(vitamin B6), diphteria anti-toxin and so on, until the discovery 
of prontosil. In 1935, Gerhard Domagk reported his discovery that a sulfanil-
amide derivative, prontosil had an astonishing effect to treat patients for 
infectious diseases like sepsis. The strong effect of this life-saving drug 
was reported one after another, and many physicians felt that the new era in 
therapy had been opened and drugs had become to have important role in thera-
py''. Subsequent introduction of various life-saving drugs such as many sulf-
anil-amide derivatives, antibiotics represented by penicillin and so on, gave 
us too much confidence in drugs and dismissed from our minds the famous words 
described by Paracelsus, "All things can be poisons. for there is nothing with-
out poisonus qualities. It is only the dose which makes a thing a poison.".
      The first 
the importance of 
Subsequently, many 
were pointed out, 
Distrust seems to 
tests during these
important therapeutic disaster which prompted us to remember 
the safety of drugs was thalidomide phocomelia in 1961. 
adverse drug reactions (ADRs) and/or toxicities of drugs 
and distrust in drug was strongly implanted in our minds. 
be gradually decreasing by stricter pre- and post-marketing 
two decades. The idea of Paracelsus' words is going to be
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recognized by laymen as well by specialists in drugs. 
strong demand that drugs should be in higher level of
We meet, however, 
etv than other pro-
ducts because drugs are materials to maintain our health and to cure disease
On the other hand, we have problems related to the economics of new drug deve-
lopment which is apparent in the development of orphan drugs because of huge 
expenditures for safety tests. 
      Safety of drug has been one of the most important subjects in the 
pharmaceutical fields and also in the public, but the discussions between 
both areas have not been performed under a common background because of the 
complexity of its factors. It is important, I believe, that people in diffe-
rent fields must be able to discuss problems on drug safety under the common 
bases and to have the same recognition to drug safety. I would ,therefore, 
like to present here the outlines of ADR problems and an essay on safety of 
drugs as related to ADR to make common backgrounds among persons in various 
 fields. 
Outlines of Drug Safety Problems in Japan
      In Japan, drugs like herb medicines were brought from China and had 
been used for more than 1,000 years. After the modern goverment was estab-
lished in 1868, the medical systems were rapidly westernized, and western 
drugs became to be used widely. Health hazard problems accompanied with the
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use of drugs were related with the intoxication by impurities and/or overdose 
of a powerful drug through the history of drugs before 1950. During the 
period, the supply of good quality drugs was rather the important problem on 
 drugs. 
      Penicillin was introduced into Japan as a strong weapon against in-
fective diseases in the confusing society after the second world war. It 
was available easily in the begining of the 1950's, and penicillin shock 
became gradually a subject in the medical community. In 1956, a famous pro-
ffessor died form the shock by penicillin in dental treatment. The press 
reports on this accident induced the flood of reports on similar penicillin 
shock cases in journalism. It is a typical pattern that potential ADR cases 
have been accumulated and a report on special cases set a fire on the ADR 
problem. 
      Outlines of drug safety problems after the penicillin shock issue are 
summerized in Table 1. The thalidomide disaster was found in Japan as well as 
                        Table 1 
in European countries after the warning by Dr Lentz in 1961. This prompted us 
to recognize the necessity of more and stricter toxicological tests of drug 
candidates and of ADR monitoring system. It was confirmed that there were 
309 cases of thalidomide phocomelia, and 185 persons including victims and
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their families brought civil actions against the goverment and six related 
pharmaceutical companies since  19632'. After the long debate in the court, 
the cases reached settlements through reconciliation. In Table 2 are summer-
ized outlines of suit cases relating to ADR including thalidomide phocomelia. 
                        Table 2 
      The next big issue was case of sudden death after takeing liquid 
medicine for cold contained in ampule(OTC). The cases appeared in 1965 though 
they had been reportedly occurring since 1959. The event threw light again 
on the importance of biological availability. 
      An unknown disease following the treatment of intestinal diseases 
appeared in Japan since 1955, and was named ,in 1964, "Subacute Myelo-Qptic 
Neuropathy" or "SMON" after dysfunction of spinal cords, optic nerves, and of 
peripheral nerves such as dysesthesia and weakness in the lower extremities, 
numbness, optic atrophy, and disturbances of vision. SMON patients increased 
gradually and the goverment undertook the special studies to elucidate the 
cause of SMON. Some investigators proposed that SMON was caused by a virus. 
The communicable nature of viruses and the tragic symptoms of SMON invited 
the discrimination of SMON patients and their families in their community. 
The issue became a large social problem. The study eventually elucidated 
that the green material peculiar to urine, feces and tung of SMON patients
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was a complex of chinoform with iron, and that most of SMON patients had took 
chinoform preparations for treatment of their intestinal diseases before 
catching  SMON. Chinoform preparations were, therefore, withdrawn from the 
Japanese market in 1975, and new SMON cases decreased rapidly. It is esti-
mated that more than 11,000 persons suffered SMON in Japan3?. Chinoform was 
used for more than 70 years in Japan, and most of SMON cases were occuring 
during the last 15 years. This largest ADR disaster in Japan prompted us 
to bring the importance of the Paracelusus' words previously mentioned to our 
mind. SMON victims more than 6,000 and their families brought civil actions 
against the goverment and 22 pharmaceutical companies since 1971, as shown in 
the Table 2. The defendants lost many of the first traials and have appealed 
to the higher court by raising the point why the occurence of SMON could not 
be considered from the medical knowledge before the relation of chinoform 
with SMON was pointed out. Apart from the appeal, the reconciliation to 
relief SMON victims has been established between most of the victims and 
defendants through the courts. The disaster led, in 1979, to the amendments 
of the Pharmaceutical Affairs Law which reinforced the efforts for safety 
measures, and the establishment of a new law, that is, the Adverse Drug 
Reactions Sufferings Rilief Fund Law which provided that the Fund should pay 
some amount of money to the serious ADR victims and collect money from pharm-
aceutical companies in proportion to the selling amount and to the paying 
amount to the victims of a paticular drugs with ADR.
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      In the midst of disputing SMON issues, various ADR victims and their 
families brought civil actions as shown in Table 1 and 2. The ADR problems 
were liver damage by a coronary vasodilator(coralgil), hearing disorder by an 
antibiotic(streptomycin), vision dsiorder by an antiinflamatory and antipro-
zoal agent(chloroquine), blood doisorder by an antibiotic(chloramphenicol), 
muscle atrophy by  intramusclar injections, and so on. Among these ADR problems 
, muscle atrophy seemed to be a problem worth writing here, as the problem 
was unique to Japan. In several areas, it was found that young children had 
difficulty to walk and had quadriceps contracture. It was, thereafter, 
pointed out that the quadriceps contracture was caused by the frequent intra-
musclar injections to the quadriceps when the children caught common cold or 
other diseases. Representatives of victims raised two points, that is, the 
negligence of physicians concerning the injuring properties of injections and 
the negligence of pharmaceutical manufacturers who had not informed on non-
physiological properties of injection drugs to physicians. Victims and their 
families brought civil actions against goverment, prefectural offices, city 
offices, pharmaceutical companies, the Japan Medical Association, hospitals 
and physicians. The characteristic of this case was that people in medical 
field became defendants by the claim that they did malpractice. In some of 
the first trials, district courts ordered pharmaceutical companies and physi-
cians to pay compensations. New cases of quadriceps contracture decreased
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 rapidly after the start of the suits. 
       I have presented here the outlines of some of ADR problems in Japan 
which were caused by negligence of medical people concerning essential quali-
ties of drugs described by Paracelusus. The neglegence might be caused by 
the lack of scientific knowledge and the deficiency of ADR information systems 
 . On the basis of these experiences, ADR information systems have been imp-
roved by the establishment of ADR monitoring systems, and by leagal obliga-
tions for pharmaceutical manufacturers to report ADR cases, to do postmarket-
ing  surveilances(PMS), and to promote the exchange of ADR information in the 
medical community. We have not had any large ADR problems scince 1975. 
However, we meet sometimes rare but serious ADR cases like shocks by iodo-
contrast media which are believed to be inevitable ADR on the use of the drug 
. We have esatblished the relief system for victims as mentioned above. Now 
, we should make efforts to know the present situation of ADR and to decrease 
such unhappy cases. In the next section, I will try to describe how often 
ADRs occurr.
frequency of ADR found in the PMS in Japan
      ADR frequency of a drug might be dependent on various factors such as 
the definition of ADR, the observers, the patient groups and the condition of 
diseases. It is, therefore, difficult to compare the results of PMS perform-
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ed under different protocols and to interpret their meaning. But the results 
might give us the round figures of ADR frequency and help us to know how 
often drugs cause ADRs. 
       In Japan, several hundred to few thousand cases on a drug are invest-
igated before approval, and several thousand to more than ten thousand cases 
on a drug are investigated in a PMS. PMS results of several groups of drugs 
are summerized in Table 3. The table shows that the drug for common disea-
                           Table 3 
es like antipyretic-analgesic and antiinframmatory agents, minor tranqui-
lizers, drugs acting circulatory systems or antibiotics causes ADR in several 
cases per a hundred while the drugs for more serious diseases such as malig-
nant tumor, schizophrenia or parkinsonism cause ADR in the order of one tenth 
 . The lists of ADR are shown on two drugs, that is, haloxazolam (minor-tran-
quilizer) and  cefmetazole (antibiotics acting mainly on gram-positive and 
gram-negative bacteria) in Tables 4 and 5,respectively. 
        Table 4Table 5 
The frequent ADRs of haloxazolam (PMS on 21,822 cases) were the following: 
      • central and peripheral nervous disoreders including dizziness(296 
        cases, 1.4%), head ache(66cases, 0.3%) and 8 other ADRs. 
• psychiatric disorders including somnolence(286 cases, 1.3%), rest-
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        less(11 cases, 0.1%) and 13 other ADRs. 
 • general systemic disorders including fatigue(76 cases, 0.3%), 
          adynamia(36 cases, 0.2%) and 3 other cases. 
These ADRs seems to be not serious although the terms needed for recovery 
 from ADR was not reported. The frequent ADRs found in cefinetazole PMS (24, 
283 cases) are the following: 
• liver function disorders including GOT elevation(208 cases, 0.85%) 
, GPT elevation(202 cases, 0.83%), jaundice(1 case, 0.004%) and 5 
         other ADRs. 
      • hypersensitiveness including eruption(196 cases,0.81%), itching(25 
         cases,0.10%), pyrexia(22 cases, 0.09%) and 3 other ADRs. 
• stomach and intestinal disorders including nausea(27 cases,0.11%), 
        diarrhea(25 cases, 0.10%), vomiting(12 cases, 0.05%),melena(4 
         cases, 0.02%), hemorrhagic olitis( 1 case,0.004%), pseudomembra-
        nous colitis(1 case, 0.004%) and 5 other ADRs. 
      • blood disorders including agranulocytosis(42 cases, 0.17%), eo-
        sinophilia(18 cases, 0.07%), throabocytopenia(9 cases, 0.04%) and 
         oligocythemia(5 cases, 0.02%). 
Most of these ADRs caused by cefinetazole seem to be not serious although a 
few cases like jaundice and colitises might be serious. The term needed for 
recovery from ADR is not described in the information.
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      As mentioned above, drugs caused ADRs in the order of one hundredth 
to one tenth depending on kinds of drugs. Those ADRs could be found in PMS 
and/or clinical tests before approval, and most of them seemed to be slight 
ADRs from which patients could easily recover by the discontenuation of the 
drug. Such slight ADRs have been generally accepted as unavoidable ones to 
recover from diseases. On the other hand, a few cases of death or incurable 
injuries caused by possible ADR may bring about a social problem and decide 
the destiny of the drug. This kinds of serious ADRs are generally difficult 
to be detected in the  PMS and/or clinical tests before approval which are 
generally performed in the scale of cases less than hundred thousand. 
      The ADR Sufferings Relief Fund, however, has been recieving cases 
with serious. injuries which were undeniably caused by ADRs. An unhappy 
example is the case where a 10 years old boy who was administered an antipy-
retic-analgesic and antiinflammatory agent, an antibiotic, a hemostatic agent 
and an antiemetic agent for acute pharyngitis, caught toxic epidermal necro-
lysis and eventually lost his sight. There are various unhappy cases such as 
deathes from malignant hyperthermia by general anesthetics and/or myorelax-
ants, from shock by antibiotics, antipyretic-analgesic and antiinflammatory 
agents and/or iodo-contrast media and so on. The lethality of intravenous 
pyelography with iodo-contrast media obtained form literatures are shown in 
Table 6 as an example of the frequency of such unhappy ADRs. It shows that 
few deathes occurred per hundred thousand cases in most investigation on
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                            Table 6 
intravenous pyelography with iodo-contrast media. Scince iodo-contrast media 
for intravenous pyelography have been changed to new ones, the lethality of 
present iodo-contrast media might be lower than that in Table 6. One of 
important problems concerning with the drug safety is to prevent the rare but 
fatal or disabling ADRs which may be caused by the interaction of drugs 
with the special physical constitution and/or physiological conditions of the 
patient. 
      In this section, I have outlined the frequency and the kinds of ADRs 
of the presently available drugs in Japan. I would like to describe out-
lines of the safety measures and my comments in the next section.
 Safety Measures for Drugs
      In Table 7 are listed the major problems on safety of 
the safety measures which have been taken through the unhappy 
health hazards caused by drugs as mentioned previously. 
                          Table 7 
      I would like to try to classify causes of ADRs to the
the drugs and 
experiences in
following three
groups:
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      (a) quality: health hazards caused by a drug of inferior quality like 
       the drug contaminated by substance(s) out of the specification, for 
      example, AIDS or hepatitis caused by a blood preparation contaminated 
      by AIDS or hepatitis viruses. 
      (b) toxicity or ADR which appeared generally in people taking a drug: 
      health hazards caused by the action of a drug which people in general 
       take over a certain amount, for example, hypoglycemia caused by 
       antidiabetics, and 
      (c) toxicity or ADR which appeared under special conditions: 
      health hazards caused only under special condition by the concerted 
      action of drug, state of disease, physiological condition and consti-
      tution of the patient, for example, shock or serious eruption caused 
      by antibiotics. 
In the cassification, the sequence of (a) to (c) seems to correspond to the 
decreasing order of the ADR frequency, to the increasing order of the diffi-
culty to predict and/or detect the ADRs on the scientific basis of the pre-
clinical toxicological data or the clinical and PMS data and to the order 
increasing the importance of experiences of individual cases of the ADR. It 
goes without saying that some of ADRs like delayed ADRs or ADRs caused by the 
accumulation of more than a tolerable amount of a drug are difficult to be 
detected even if the group of ADRs is in (a) or  (b)  .
      The following measures:
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 • the performance of various safety tests on the  basis of the scien-
      tific knowledge in related fields such as medicine and pharmaceutical 
        sciences, 
        •the observance of the guidelines like GLP and GCP(still in proposal 
      )to insure the reliability of the data obtained in the safety tests, 
• prudent evaluation for approval taken by the goverment, 
• standardized production of drugs under the strict observances of 
       GMP, 
• surveilance and control of the production and marketing processes 
      by the administration offices, and 
• ADRs surveilances in various methods 
have been taken effectively against ADRs of group (a) and (b). Futher safety 
measuers against these group of ADRs would be the followings: 
      (1) deepening understanding of diseases, dynamics and control 
      mechanisms of various substances in a human body in conformitywith 
      the rapid advancements of related fundamental sciences, 
      (2) the establishment of more appropriate methods to test toxicity 
     and/or ADRs and the development of the methods, to use moreeffect-
      ively data obtained already or animal test data to investigate toxi-
     city and/or ADRs of new substances, on the basis of (1), 
      (3) the developments of new drugs which have stronger efficacy and 
     more limited ADRs than drugs available at present, and
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      (4) the consolidation of the education on  the proper use of drugs and 
      on ADRs for people in the medical field like physicians and pharma-
       cists as well as laymen. 
       ADRs in the group (c) are related to rare but serious ADRs which are 
most important as the health hazards caused by current drugs in Japan as 
mentioned previously. These ADRs are difficult to take safety measures and 
give us complicated safety problems. A part of current safety measures as 
mentioned above have played an important part in the safety measures against 
ADRs in group (c) and the expected safety measures (1) to (4) should be 
indispensable to the matter. The scarcity and complexity of ADRs in group 
(c) bring us the following questions: 
      (5) what are the adequate methods to collect information for detect-
      ing the ADRs in the very early stage of their appearance ? 
      (6) will we be able to have any preliminary tests to prevent the 
      outbreak of the ADRs ? 
      and in adddition to these scientific aspects, from the aspects of 
      medical economics and bioethics 
      (7) what extent of safety measures hould we take in view of the 
      cost-effectiveness ratio ? 
      Concerning the data collection as mentioned in (5), various types 
of cohort surveies have been carried out but are limited only to some groups.
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We expect to expand the sphare of this type of surveies since we are in good 
enviroments to do it by the use of the recent rapid advancement and propaga-
tion of electronic information processing and communication systems. In 
order to make a big progress in this field, methods for simple inputs of good 
quality data, way to obtain data compatibility and principles of data usage 
should be investigated in cooperation with the people in the related 
fields. In respect of information, we have another problem that informations 
on the frequency and quality of ADRs in simple and intelligible forms will be 
required for the purpose of (4) when patients will have a choice on their own 
medical treatments in the future. It will be possible to lead us to re-exa-
mination of ADRs information and to the request of quantitative ADRs data. 
Long time has passed since we started the collection, evaluation and circula-
tion of ADRs information. These were important to ensure the safety of drugs, 
but we still have many problems which should be improved in this field. 
Answer to question (6) will be found of itself by the fruit of studies des-
cribed in (1) and (2), and by the development of ADR data collection system 
as mentioned above. 
     As regards to question (7), the expenditure to detect or prevent ADRs 
has been calculated as the function of ADR occurrence probability, sponta-
neous appearance rate of the disease similar to the  ADR and the cost of 
survey or test. It shows that huge expenditure is required to detect or 
prevent a case of quite rare ADR. At present, a general opinion on life and
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health of human is that life and health should be kept in the highest level 
of medicine, and does not contain the idea on cost-effectiveness ratio. 
Social consensus on cost-effectiveness ratio in medical field, however, will 
become necessary as the expensive treatment will increase with the advance-
ments of medical technology. The pursing limit of drug safety measures also 
will be discussed from the view of cost-effectiveness ratio, and it will be 
necessary to make efforts for establishing social consensus on drug safety. 
We, therefore, should endivor to make consensus on the evaluation of life and 
health, and accumulate more quantitative data on drug safety which is rather 
qualitative at the present. 
      As the conclusion of the discussion as described above, I consider 
that the pursit of the  mures and questions (1) to (7) is important sub-
jects to improve the drug safety in the future. The followings: 
       • that the rapid advancements of biological sciences will be used 
      swiftly to evaluate and/or test the drug safety, 
       • that the recent rapid advancement and propagation of electronic 
      information processing and communication systems will be used to 
      establish the collection and circulation systems of ADRs information 
      in improved quality, and, 
       • that the practical limit of the drug safety measures will be dis-
      cussed by the people in more various field, 
 may be especially important.
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 Summary  
      People in general take an interest in the safety of drugs but limited 
people in the medical and pharmaceutical fields only take part in debates on 
drug safety except for some special cases which became journalistic topics. 
Aiming at the way to improve the safety of drugs in cooporation with the 
experts in various safety problems, I have introduced thefollowing topics: 
      1. health injuries related with drugs which became objects of public 
        concern, 
      2. frequency and quality of ADRs observed in PMS on some currently 
      available drugs, and 
      3. outlines of current safety measures for drugs, 
focusing on experiences in Japan. 
     I have also pointed out that rare but serious health injureies are 
an important problem on the drug safety although they were caused by the 
complicated combination of the drug action, physiological condition and/or 
pysical constitution of a patient. Concerning about rare but serious ADRs, 
I have suggested that important measures are the followings: 
      1. investigations on the detection and/or evaluation methods in swift 
     response to the rapid advancement of related sciences, 
     2. consolidation of the system collecting and distributing ADRs
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 information by use of rapid advancements and propagation of electro-
nic information processing and comunication systems, 
3. enrichment of ADRs information to debate the cost-effectiveness 
ratio on drug safety and to make the consensus on the pursing limit 
of drug safety measures.
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Table 1  Outlines  of Drug Safety Problems in Japan
YearDru Safety Problems
1956 
1961 
1965 
1970 
1971
1975
1976 
1977
1978 
1979
Penicillin shock became a social problem through the death of 
a famous professor. 
Warning about thalidomide in relation with the birth of phoco-
melia babies. 
Sudden deathes after taking ample prepareations of medicenes 
for cold. 
Warning that SMON might be caused by chinoform. 
Liver disorder by coraliil was pointed out. 
SMON cases were presented to the civil courts. 
Coralgil cases were presented to the civil court. 
Streptomycin cases were presented to the civil court. 
Vision disorder by chloroquine became a social issue and the 
cases were presented to the court. 
Muscle atrophy caused by intramusclar injections was warned 
by a group of physicians and the cases were presented to the 
civil court. 
Ministry of Health and Welfare(MHW) esatblished a working 
group to investigate a relief system for the ADR sufferings. 
Report for the relief system was presented by the group. 
The first reconciliation in SMON cases was established in the 
Tokyo district court. 
Draft of ADR Sufferings Relief Law was published by MHW. 
Draft of the amendments of Pharmaceutical Affairs Law was 
publised by MHW. 
Amendment Law of Pharmaceutical Affairs Law and Adverse Drug 
Reaction Sufferings Relief Fund Law were adopted in the 
National Diet and enforced.
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Table 2 Principal Suit Cases  Concerning with ADR Probl
Case Name Date of 
Action
Number of 
Courts
Number of 
Plaintiff
Defendants Amount 
Claimed
thalidomide 1963
1971
.6.17. 
to 
.9.2.
District 8 
(Tokyo etc)
  185 
(patients 
  63 )
goverment 
5 pharm. 
companies
  3,275 
(million V)
chinoform 1971
1985
.5.28. 
to 
.12.6.
District 32 
Higher 7 
(Tokyo etc)
 7,635 
(patients 
6,455)
goverment 
22 pharm. 
companies
284 992
chloram-
phenicol
1975
1978
.7.31. 
to 
.10.3.
District 
(Tokyo)
1 12 
 (patients 
   5)
goverment 
3 pharm. 
companies 
11 physicians
411
muscle 
atrophy
1975
1980
.7.31. 
to 
.10.20.
District 3 
Higher3 
(Tokyo etc)
  944 
(patients 
 318)
goverment 
prefecture 
2 cities 
31 pharm. 
companies 
Jap. Med.A. 
6 hospital 
20 physicians
12,036
chloroquine 1975
1985
.12 
to 
.11
.22. District 2 
   Higher 1
.29. (Tokyo etc)
   282 
(patients 
 95)
goverment 
6 pharm. 
companies 
14 hospital 
• physicians
18,882
chlotaone 1976.2.6. District 1 
(Tokyo)
    14 
(patient 
  1)
goverment 
1 pharm. 
company 
1 hospital 
• physician
112
strepto-
mycin
coralgil
1971.9.16.
1971.11.20. 
   to 
1980.5.20.
District 1 
(Tokyo)
District 8 
(Tokyo etc)
    4 
(patient 
  1)
   56 
(patients 
  29)
goverment 
4 pharm. 
companies 
1 physician 
goverment 
1 company
28
864
This table was quoted 
6lyear version" edited 
Health and Welfares,
from 
by 
1986
"Recent Administration on Pharmaceutical 
Pharmaceutical Affairs Beureau, Ministry 
, Yakumu-Koho-sha, Tokyo
Affairs 
of
- 115 -
Table 3 ADR  Frequen found i some Qf PtS in Japan
Group Drug Name Date of Number of Frequency
     Approval PMS cases of ADR 
Antipyretic-
Analgesic and 
Antiinflamma-
tory Agents
acetaminophen(supposi-
tory) 
tolmetin sodium 
diclofenac sodium 
fenbufen 
tinoridine HC1
1979.08.03.
1978.08.01. 
1975.12.08. 
1979.05.22. 
1971.05.10.
6,024
15,894 
17,518 
18,184 
19,495
0.08%
4 
8 
2 
2
3 
0 
8 
1
Psycotropic 
Agents
haloxazoram 
fludiazepam 
flurazepapm HC1 
sulpiride 
levodopa-benserazide 
HC1
1980.06.10. 
1980.06.10. 
1978.08.01. 
1979.03.13. 
1979.08.27.
21 
8 
7 
15 
2
822 
752 
005 
104 
875
3 
2 
3 
15 
13
7 
6 
6 
1 
9
z 
z
Drugs Acting 
on Circulatory 
System
Antibiotics
isosorbide nitrate 
(slow reliesing agent) 
indenolol HC1 
trapidil 
clofibrate aluminum 
ifenprodil tartarate
piperacillin sodium 
talampicillin HC1 
cefmetazole sodium 
ampicillin-dicloxa-
cillin sodium 
doxycycline HC1
1981.05.01.
1978.05 
1978.05 
1978.01 
1978.05
18 
01 
24 
18
1979.05.22. 
1977.03.05. 
1978.08.01. 
1978.08.01.
1979.08.07.
9,502
5 
11 
5 
9
18 
22 
24 
4
941 
856 
524 
386
905 
219 
283 
569
5,997
3.8 %
4 
2 
4 
2
2 
5 
2 
1
0 
6 
7 
1
0 
7 
9 
9
z 
z
z 
X 
X
6.0 %
Antineoplastic 
Agents
tegaful (suppository) 
tegaful (enterics) 
fluorouracil 
nimustine HC1 
mepitiostane
1977.08.10. 
1979.05.22. 
1980.10.25. 
1979.05.22. 
1978.08.01.
5 
9 
6 
1
233 
047 
929 
007 
968
21 
14 
32 
56 
43
7 
2 
4 
9 
6
X 
z 
X
* These data were collected 
  the Pharmaceutical Affairs
from "ADR 
Bureau,
Informations"(No55 
Ministry of Health and
No76) edited by 
Welfare
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Table 4  APRs of Haloxazolam`
Kinds of ADR Number of ADR Case e
central and peripheral nervous disorders 
psychiatric disorders 
general systemic disorders 
autonomic nervours disorders 
liver and bile duct disorders 
stomach and intestinal disorders 
metabolic and nutrient disorders 
blood disorders 
urinary disorders
362 
310 
115 
39 
49 
20 
18 
17
1.7 % 
1.4 2 
0.5 2 
0.2 2 
0.2 2 
0.1 2 
0.1 2 
0.1 2 
0.0 %
* The data 
 Affairs
was cited from 
Bureau, Ministry
"ADR 
of
informations" edited by the 
Health and Welfare
Pharmaceutical
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Table 5 ADRs of CefinetazoleSodl_ui'
Kinds of ADRs  Number of ADR Cases F e
liver function disorders 
hypersensitiveness 
stomach and intestinal disorders 
blood disoreders 
renal function disorders 
injected site disorders 
shock and shock like reactions 
vitamin deficiency 
other ADRs
482 
275 
90 
74 
38 
40 
21 
 2
1.9 % 
1.1 % 
0.4 % 
0.3 % 
0.2 % 
0.2 2 
0.1 % 
0.0 X
* This data was cited from "ADR Informations" edited by the Pharmaceutical 
  Affairs Bureau, Ministry of Health and Welfare.
— 118 —
Table 6 Lethality of Intravenous  PyelograPhy by Iod9-Contrast  Media 
Investigato s(Countr Year
Jungmichel(Germany) " 
De Becker(Bergy)2' 
Pfeiffer(Germany)3' 
Coliez(France)4' 
Burkhardt(Germany)5' 
Pendergrass (US)6' 
Nesbit(US)7' 
Wolfrom(France)8' 
Toniolo(Italy)8' 
Klumair(Austria)1O' 
Ansell(UK) "' 
Fisher(US)'2' 
Ochsner(US) 13' 
Shedai(US)t4'
   -1940 
   -1949 
   -1949 
   -1954 
   -1954 
1942-1958 
   -1959 
1955/1965 
   -1966 
1955-1967 
1966-1969 
1960/1969 
1955-1968 
   -1973
Nugber of cases
   81,000 
   60,000 
  650,000 
  300,000 
1,000,000 
11,546,000 
144,500 
  912,300 
1,200,000 
   24,050 
  318,500 
3,837,695 
41,308 
   47.678
ases of Death Lethality 
2 
1 
35 
9 
7 
99 
1 
15 
14 
0 
8 
74 
1 
5
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0
.
0025 % 
0017 % 
0055 Z 
003 % 
0007 % 
00086% 
0007 % 
0016 % 
0012 % 
00000% 
0025 % 
0019 % 
0024 X
* This table was 
  Affairs Bureau
quoted from 
, Ministry of
"ADR Informations" 
Health and Welfare
edited by the Pharmaceutical
1) 
2) 
3) 
4) 
5) 
6) 
7) 
8) 
9) 
10) 
11) 
12) 
13) 
14)
Munch. med. Wschr. 393. 1940 
J. radio. delectrol 36,7/8:572,1964 
Grundlage d. funkt. Nierendiagnostik, 
J. radiol. Electrol. 47:358,1966 
Z. Urol. 47:13,1954 
Radiology 71,1:1,1958 
Knappschaftsarzt 39:55,1970 
J. radiol. Electrol. 47:346,1966 
Radiol. Med. 52:625,1966 
Wien med. Wschr. 118,44:931,1968 
Invest. Radiol. 5,6:374,1970 
Radiology 103:497,1972 
South med J. 64,8:967,1971 
International Congress of Radiology in
Stuttgart
Madri. ,
1949
1973
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Table 7 Problems and Measuers  _Concerning the Safety of_Drugs
Safety Problems Safety Measuers
Resarch and
Development
Appro-
val
Quality: 
• products out of spe-
 cification 
• change in quality 
• counterfeit drugs 
• contamination of 
 impurity or poisonus 
 substances (e.g. 
 AIDS or hepatitis by 
 blood preparation) 
• criminal addition of 
 poisonus substance in 
 marketing process
Approval:
*forgery of documents 
for approval applica-
 tion
Toxicity and ADRs
• ADRs
• accidents by misuse 
 (overdose, to take 
 packaged rug, etc) 
.accidents under drug 
 effects
• drug addiction
Quality: 
• specification(purity, 
 contents,solubility ) 
• stability test 
• package 
Toxicity and ADRs 
• good laboratory pra-
 ctices(GLP)
• genral toxicity test 
 (acute, subacute, 
 chronic) 
• special toxicity test 
  effect on reproduc-
  tion 
 mutagenicity 
carcinogenicity 
 local irritation 
  antigenicity 
 dependence 
• absorption ,metabolism, 
 excretion 
 bioabailability 
 metabolic activation 
 distribution,storage
• good clinical practice 
(GCP) 
• clinical tests
• establishment of 
 indication, dose, 
 dosage, and direction 
 for use
pruden-
t 
evalua-
tion by 
experts 
of 
various 
fields
Manufacturing 
and Marketing 
Quality: 
• Good Manufactureing 
 practices (GMP) 
• surveilances by 
 adminstration 
offices
Toxicity and ADRs 
• contenuous survey 
 of literatures 
• re-evaluation of 
 old drugs 
• ADRs monitoring 
• post-marketing 
surveilances(PMS) 
• reporting duty of 
 new and/or serious 
 ADRs for pharmaceu-
 tical manufactuerer 
• special studies on 
 ADRs such as epide-
 miological saurvey 
• surveilances of 
 advertisements by 
 administration 
 office 
• reversion of labe-
 ling by administ-
 ration office 
• supply of ADRs 
information to 
 medical proffesion 
• administerative 
 orders(special test 
 ,change of dose, 
 dosage and indica-
 tion. withdrawal)
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